Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Crohn’s Disease Treatment Market Evolve in Terms of Growth and Size by 2029?

In recent times, there has been significant growth in the market size of Crohn’s disease treatment. The market is projected to expand from $12.45 billion in 2024 to hit $13.1 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.2%. The past growth is linked to several factors such as rising prevalence of the disease, improvements in diagnostic methods, the use of biological therapies, greater patient awareness and education, and advances in clinical research and development.

It is anticipated that the market size for Crohn’s disease treatment will witness significant growth in the coming years, potentially reaching a market value of $17.34 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.3%. This projected growth during the forecast period is linked to multiple factors such as the rise of personalized medicine, expansion of the biologics market, shifting treatment guidelines, increased spending in healthcare, and collaborative research initiatives. Future trends projected for the forecast period include the use of telemedicine for managing patients, research into immune modulation strategies, patient-focused care models, and the incorporation of digital health solutions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10852&type=smp

What factors are expected to fuel Crohn’s Disease Treatment market growth in the coming years?

The escalating occurrence of inflammatory bowel disorders is predicted to drive the expansion of the market for Crohn’s disease treatment. These disorders collectively signify chronic conditions causing inflammation of the gastrointestinal tract, leading to inflammation and damage from the mouth to the anus. The role of Crohn’s disease treatment is to reduce this intestinal inflammation, control symptom outbreaks, and maintain remission. For example, data from the US-based National Center for Biotechnology Information in September 2023 indicated a coinciding rise in the prevalence of Crohn’s disease and ulcerative colitis. It projected an approximate incidence of inflammatory bowel disease at 825 cases per 100,000 people in 2023 – 410 for Crohn’s disease and 414 for ulcerative colitis and IBD-u. Therefore, the accelerating incidence of these conditions is propelling the growth of the Crohn’s disease treatment market.

What Are The Key Findings From The Segmentation Analysis Of The Crohn’s Disease Treatment Market?

The crohn’s disease treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other Applications

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Other Antibiotics

2) By Amino Salicylates: Mesalamine, Sulfasalazine, Other Amino Salicylates

3) By Corticosteroids: Prednisone, Budesonide, Other Corticosteroids

4) By Immunomodulators: Azathioprine, Methotrexate, Mercaptopurine

5) By Other Drug Types: Biologics, Small Molecules, Other Treatments

Which Trends Are Expected To Shape The Future Of The Crohn’s Disease Treatment Market?

Leading corporations in the crohn’s disease treatment market are introducing new medications and securing their approval, such as the biosimilar ustekinumab, with the aim to heighten effective treatment accessibility and uplift patient results and lifestyles. The term biosimilar ustekinumab denotes a biologic treatment that closely replicates the original ustekinumab, a monoclonal antibody deployed in managing autoimmune disorders. For example, in July 2024, Pyzchiva (ustekinumab) was released across Europe by Switzerland-based pharmaceutical firm, Sandoz International GmbH, hence being identified as the first ustekinumab biosimilar accessible in all dosages, including a 130 mg vial intended for Crohn’s disease specifically. This product is recommended for adults and children above six suffering from plaque psoriasis, psoriatic arthritis, and Crohn’s disease, with the objective of enhancing Sandoz’s immunology catalog while aiming to facilitate more affordable treatment options for chronic inflammatory disease.

What Are The Most Active Companies In The Crohn’s Disease Treatment Market Today?

Major companies operating in the crohn’s disease treatment market include AbbVie Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Bristol-Myers Squibb Company, Galapagos NV, Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Mylan N.V., Glenmark Pharmaceuticals, Tillotts Pharma AG, Dr. Falk Pharma GmbH, Shire Pharmaceuticals, Salix Pharmaceuticals, Prometheus Laboratories Inc., Arena Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

Which Regional Markets Are Attracting The Most Investment In Crohn’s Disease Treatment?

North America was the largest region in the global Crohn’s disease treatment market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the Crohn’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10852&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model